Skip to main content
Clinical Trials/NCT00998972
NCT00998972
Completed
Phase 3

Preventive Administration of N-acetyl-cysteine (NAC) in Organ Donor: Effects on Kidney Graft Function

Institut d'Anesthesiologie des Alpes Maritimes1 site in 1 country236 target enrollmentSeptember 2006

Overview

Phase
Phase 3
Intervention
N-acetylcysteine
Conditions
Brain Death
Sponsor
Institut d'Anesthesiologie des Alpes Maritimes
Enrollment
236
Locations
1
Primary Endpoint
Incidence of delayed graft function
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The goal of this study is to evaluate the effect of N-acetyl-cysteine (NAC) administration in organ donors on the kidney graft function of recipients.

Detailed Description

Ischemia-reperfusion is a major contributing factor for delayed renal function after transplantation. It has been shown that the administration of an antioxidant, i.e. NAC, in patients with chronic renal insufficiency may prevent radio contrast-induced nephropathy. Due to its antioxidant effects, organ donor pretreatment with NAC has demonstrated to improve renal graft function in two experimental studies. Study objectives: to compare the incidence of delayed graft renal function between two groups of patients, i.e., those receiving the graft from organ donors pretreated with NAC and a group control. The primary endpoint was the number of delayed graft function defined as the requirement of at least one sequence of dialysis during the first seven days following transplantation. Secondary endpoints: evolution of creatininemia, azotemia at day 1, 7, 14 and ,30 after surgery; acute and delayed transplant rejection; intrahospital mortality. Patients inclusion: all organ donors and recipients were eligible Exclusion criteria: for organ donors were preexistent chronic renal insufficiency and contra-indications for kidney procurement; for recipient were transplantation outside our hospital The donors were randomized in a single-blind fashion into two groups : the control group and the group receiving 600 mg IV of NAC 1 hour before and 600 mg IV 2 hours after cerebral arteriography required to diagnose brain death. Sample size has been calculated delayed graft function by 50% leading to include 118 recipients in each group. Follow up: one year after transplantation. Study beginning in september 2006. Length of inclusion during 36 months.

Registry
clinicaltrials.gov
Start Date
September 2006
End Date
June 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Institut d'Anesthesiologie des Alpes Maritimes

Eligibility Criteria

Inclusion Criteria

  • all recipient for kidney graft in our hospital

Exclusion Criteria

  • transplantation out side our hospital
  • refusal from the patient

Arms & Interventions

N-acetylcysteine

administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death

Intervention: N-acetylcysteine

Outcomes

Primary Outcomes

Incidence of delayed graft function

Time Frame: 1 year

Secondary Outcomes

  • Evolution of creatininemia and azotemia during the first month after transplantation(30 days)
  • Intrahospital mortality(30 days)
  • Acute and delayed graft rejection(30 days)

Study Sites (1)

Loading locations...

Similar Trials